Search results for "Phoma"

showing 10 items of 716 documents

Incidence of childhood cancer of the head and neck in Germany.

2007

Background: Only very limited data are available in the literature on the incidence of childhood cancer of the head and neck worldwide. Methods: Based on data obtained from the national German Childhood Cancer Registry, a total of 370 malignancies of the head and neck in children under the age of 15 (199 boys and 171 girls), which were reported to this institution between 1994 and 2003, were analysed in this study. Results: The overall incidence of malignancies of specific sites of the head and neck in Germany is 4.48 per 100000 children. The most frequently observed entities, representing primary tumours, are soft tissue sarcomas (0.39/100000), lymphomas (0.09/100000) and thyroid carcinoma…

MalePediatricsmedicine.medical_specialtyAdolescentNeuroblastomaGermanyEpidemiologymedicineHumansThyroid NeoplasmsChildChildhood Cancer Registrybusiness.industryIncidence (epidemiology)IncidenceLymphoma Non-HodgkinHead and neck cancerInfant NewbornCancerInfantNasopharyngeal NeoplasmsSarcomaHematologymedicine.diseaseSurgeryParanasal sinusesmedicine.anatomical_structureOncologyEl NiñoHead and Neck NeoplasmsTonsilChild PreschoolFemalebusinessAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Whole-body diffusion-weighted MR and FDG-PET/CT in Hodgkin Lymphoma: Predictive role before treatment and early assessment after two courses of ABVD

2017

Abstract Purpose To evaluate whether imaging features of pathologic lymph nodes on whole-body diffusion-weighted MR have a predictive role before treatment and may assess the response after two courses of chemotherapy in comparison to FDG-PET/CT in Hodgkin Lymphoma. Materials and methods We reviewed the whole-body MR and FDG-PET/CT performed on 41 patients with Hodgkin Lymphoma before and after two Doxorubicin-Bleomycin-Vinblastine-Dacarbazine (ABVD). Responder and non-responder lesions were identified on interim-FDG-PET/CT performed after two ABVD. We used Multivariate Generalized Estimating Equations model to assess statistical association between being-responder and baseline-Maximum Stan…

MalePredictive Value of Test030218 nuclear medicine & medical imaging0302 clinical medicinePositron Emission Tomography Computed TomographyAntineoplastic Combined Chemotherapy ProtocolsWhole Body ImagingStage (cooking)medicine.diagnostic_testGeneral MedicineMiddle AgedHodgkin DiseaseDacarbazinePositron emission tomography030220 oncology & carcinogenesisPredictive value of testsRadiopharmaceuticalFemaleRadiologyHumanmedicine.drugAdultPositron emission tomographymedicine.medical_specialtyAdolescentDacarbazineWhole body imagingStandardized uptake valueVinblastineBleomycinYoung Adult03 medical and health sciencesMagnetic resonance imagingPredictive Value of TestsFluorodeoxyglucose F18medicineHumansRadiology Nuclear Medicine and imagingAgedAntineoplastic Combined Chemotherapy ProtocolHodgkin Lymphomabusiness.industryABVDDiffusion weighted imagingMagnetic resonance imagingDiffusion Magnetic Resonance ImagingABVDDoxorubicinRadiopharmaceuticalsbusinessEuropean Journal of Radiology
researchProduct

Single-dose Palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving mode…

2011

PURPOSE: The control of nausea and vomiting induced by chemotherapy is paramount for overall treatment success in cancer patients. Antiemetic therapy during chemotherapy in lymphoma patients generally consists of anti-serotoninergic drugs and dexamethasone. The aim of this trial was to evaluate the efficacy of a single dose of palonosetron, a second-generation serotonin type 3 (5-HT(3)) receptor antagonist, in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy (MEC) containing steroids. METHODS: Patients received a single intravenous bolus of palonosetron (0.25 mg) before administration of chemotherapy. Complete response (CR) defined as no vomiting …

MaleQuinuclidinesmedicine.medical_treatmentCINVCHOPGastroenterologyDexamethasoneSettore MED/15 - Malattie Del SangueAntineoplastic Combined Chemotherapy ProtocolsSerotonin 5-HT3 Receptor AntagonistsProspective StudiesAged 80 and overLymphoma Non-HodgkinPalonosetronNauseaMiddle AgedEmesisPalonosetronTreatment OutcomeOncologyAnesthesiaCHOP CINV Emesis Nausea NHL PalonosetronVomitingFemaleOriginal Articlemedicine.symptomCHOP-CINV; emesis; nausea; NHL; Palonosetronmedicine.drugAdultmedicine.medical_specialtyVomitingNauseamedicine.drug_classNHLYoung AdultInternal medicinemedicineHumansAntiemeticGlucocorticoidsAgedChemotherapybusiness.industryIsoquinolinesmedicine.diseaseNon-Hodgkin's lymphomaAntiemeticsbusinessCHOPChemotherapy-induced nausea and vomiting
researchProduct

Maternal Supplementation with Folic Acid and Other Vitamins and Risk of Leukemia in Offspring

2014

Maternal prenatal supplementation with folic acid and other vitamins has been inconsistently associated with a reduced risk of childhood acute lymphoblastic leukemia (ALL). Little is known regarding the association with acute myeloid leukemia (AML), a rarer subtype.We obtained original data on prenatal use of folic acid and vitamins from 12 case-control studies participating in the Childhood Leukemia International Consortium (enrollment period: 1980-2012), including 6,963 cases of ALL, 585 cases of AML, and 11,635 controls. Logistic regression was used to estimate pooled odds ratios (ORs) and 95% confidence intervals (CIs), adjusted for child's age, sex, ethnicity, parental education, and s…

MaleRiskMyeloidAdolescentChildhood leukemiaEpidemiologyOffspringPhysiologyArticleFolic AcidPregnancyRisk Factorshemic and lymphatic diseasesmedicineHumansChildMaternal-Fetal ExchangeChildhood Acute Lymphoblastic LeukemiaPregnancybusiness.industryInfant NewbornCase-control studyInfantMyeloid leukemiaVitaminsPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseLeukemia Myeloid AcuteLeukemiamedicine.anatomical_structureCase-Control StudiesChild PreschoolDietary SupplementsFemalebusinessEpidemiology
researchProduct

The interleukin (IL)-31/IL-31R axis contributes to tumor growth in human follicular lymphoma

2014

Interleukin (IL)-31A binds to an heterodimer composed of IL-31 receptor A (IL-31RA) and Oncostatin M Receptor (OSMR). The IL-31/IL-31R complex is involved in the pathogenesis of various skin diseases, including cutaneous T-cell lymphoma. No information is available on the relations between the IL-31/IL-31R complex and B-cell lymphoma. Here we have addressed this issue in follicular lymphoma (FL), a prototypic germinal center(GC)-derived B-cell malignancy. IL-31 enhanced primary FL cell proliferation through IL-31R-driven signal transducer and activator of transcription factor 1/3 (STAT1/3), extracellular signal-regulated kinase 1/2 (ERK1/2) and Akt phosphorylation. In contrast, GC B cells d…

MaleSTAT3 Transcription Factormedicine.medical_specialtyCancer ResearchPrimary Cell CultureFollicular lymphomaBiologyParacrine signallingCytosolCell-Derived MicroparticlesInternal medicinemedicineHumansProtein IsoformsPhosphorylationAutocrine signallingLymphoma FollicularCell ProliferationMitogen-Activated Protein Kinase 1B-LymphocytesMitogen-Activated Protein Kinase 3Gene Expression Regulation LeukemicInterleukinsMicrovesicleMedicine (all)Cell MembraneB-LymphocyteGerminal centerOncostatin M receptorInterleukinProtein IsoformReceptors InterleukinHematologyInterleukinMiddle Agedmedicine.diseaseGerminal CenterMolecular biologyCell-Derived MicroparticleEndocrinologySTAT1 Transcription FactorAnesthesiology and Pain MedicineOncologyFemaleSignal transductionNeoplasm GradingProto-Oncogene Proteins c-aktHumanSignal Transduction
researchProduct

Interleukin (IL)-22 receptor 1 is over-expressed in primary Sjogren's syndrome and Sjögren-associated non-Hodgkin lymphomas and is regulated by IL-18.

2015

Summary The aim of this study was to elucidate more clearly the role of interleukin (IL)-18 in modulating the IL-22 pathway in primary Sjögren's syndrome (pSS) patients and in pSS-associated lymphomas. Minor salivary glands (MSGs) from patients with pSS and non-specific chronic sialoadenitis (nSCS), parotid glands biopsies from non-Hodgkin lymphomas (NHL) developed in pSS patients, were evaluated for IL-18, IL-22, IL-22 receptor 1 (IL-22R1), IL-22 binding protein (IL-22BP) and signal transducer and activator of transcription-3 (STAT-3) expression. MSGs IL-22R1-expressing cells were characterized by confocal microscopy and flow cytometry in pSS, nSCS and healthy controls. The effect of recom…

MaleSalivary Glandslaw.inventionInterleukin 22lawIL-22Immunology and AllergyMyeloid CellsIL-22R1Receptormedicine.diagnostic_testnon-Hodgkin lymphomaLymphoma Non-HodgkinInterleukin-17TranslationalInterleukin-18Lacrimal ApparatusInterleukinMiddle AgedHaematopoiesisSjogren's SyndromeIL-22BPRecombinant DNASjögren's syndromeInterleukin 18FemaleIL-18Signal TransductionAdultSTAT3 Transcription FactorImmunologyPrimary Cell CultureBiologyPeripheral blood mononuclear cellIL-18; IL-22; IL-22BP; IL-22R1; Sjögren's syndrome; non-Hodgkin lymphomaSialadenitisFlow cytometrystomatognathic systemmedicineHumansAgedInterleukinsMacrophagesReceptors InterleukinSettore MED/16 - Reumatologiastomatognathic diseasesGene Expression RegulationImmunologyLeukocytes MononuclearClinical and experimental immunology
researchProduct

Cytostatic Activity of Aeroplysinin-1 against Lymphoma and Epithelioma Cells

1989

(±)-Aeroplysinin-1, an optically active 1.2-dihydroarene-1.2-diol. was isolated from the marine sponges Verongia aerophoba (+-isomer) and lanthella ardis (--isomer). For the experiments presented we used the +-isomer from Verongia aerophoba. Here we describe the hitherto unknown biological and pharmacological property of this compound to display pronounced anticancer activity against L5178y mouse lymphoma cells (ED50: 0.5 μm). Friend erythroleukemia cells (ED50: 0.7μm) , human mamma carcinoma cells (ED50: 0.3μm) and human colon carcinoma cells (ED50: 3.0 μm) in vitro. Furthermore, aeroplysinin caused a preferential inhibition of [3H]thymidine (dThd) incorporation rates in L5178y mouse lymph…

MaleSalmonella typhimuriumAcetonitrilesCell SurvivalCellAntineoplastic AgentsMice Inbred StrainsBiologyGeneral Biochemistry Genetics and Molecular BiologyCell LineMicechemistry.chemical_compoundIn vivoCyclohexenesTumor Cells CulturedmedicineCarcinomaAnimalsHumansLeukemia L5178ED50Leukemia ExperimentalMutagenicity TestsMelanomaCarcinomamedicine.diseaseVirologyMolecular biologyIn vitroLymphomamedicine.anatomical_structurechemistryDrug Screening Assays AntitumorThymidineZeitschrift für Naturforschung C
researchProduct

Comparison between whole-body MRI with diffusion-weighted imaging and PET/CT in staging newly diagnosed FDG-avid lymphomas.

2015

Abstract Objectives To compare whole body-MRI (WB-MRI) with diffusion-weighted imaging and FDG-PET/CT in staging newly diagnosed FDG-avid lymphomas. Methods 68 patients (37 males, 31 females; median age 42 years; range 15–86 years) with histologically confirmed lymphoma (37 Classical Hodgkin, 16 Diffuse large B-cell, 10 Follicular, 5 Mantle cell) underwent both MRI and FDG-PET/CT before treatment. Ann Arbor stages obtained with WB-MRI and FDG-PET/CT were compared using Cohen’s k statistics. Moreover WB-MRI and FDG-PET/CT stages were compared with the pathological stages obtained after the diagnostic iter using also bone marrow and available biopsies if clinically indicated. Results The agre…

MaleStagingLymphomaMultimodal Imaging030218 nuclear medicine & medical imaging0302 clinical medicineWhole Body ImagingProspective StudiesStage (cooking)Computed tomographyAged 80 and overmedicine.diagnostic_testGeneral MedicineMiddle AgedPositron emission tomography030220 oncology & carcinogenesisRadiopharmaceuticalFemaleDiffusion-weighted imagingRadiologyHumanmedicine.drugAdultmedicine.medical_specialtyAdolescentWhole body imagingReproducibility of ResultYoung Adult03 medical and health sciencesMagnetic resonance imagingFluorodeoxyglucose F18medicineHumansRadiology Nuclear Medicine and imagingAgedNeoplasm StagingFluorodeoxyglucosePET-CTIvermectinbusiness.industryReproducibility of ResultsMagnetic resonance imagingmedicine.diseaseLymphomaProspective StudieDiffusion Magnetic Resonance ImagingPositron-Emission TomographyMantle cell lymphomaRadiopharmaceuticalsSettore MED/36 - Diagnostica Per Immagini E RadioterapiaTomography X-Ray ComputedNuclear medicinebusinessEuropean Journal of Radiology
researchProduct

Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma

2018

Temsirolimus 175 mg once-weekly for 3 weeks, followed by 75 mg once-weekly intravenously dosed (175/75 mg) is approved in the European Union for treatment of relapsed/refractory mantle cell lymphoma (MCL). A phase IV study explored whether similar efficacy, but improved safety could be achieved with 75 mg without 175 mg loading doses (ClinicaTrials.gov: NCT01180049). Patients with relapsed/refractory MCL were randomized to once-weekly temsirolimus 175/75 mg (n = 47) or 75 mg (n = 42). Treatment continued until objective disease progression. Primary endpoint: progression-free survival (PFS). Secondary endpoints included overall survival (OS) and adverse events (AEs). Median PFS was 4.3 versu…

MaleTemsirolimusCancer ResearchLymphomaDrug ResistanceLymphoma Mantle-CellGastroenterology0302 clinical medicineAntineoplastic Combined Chemotherapy Protocols80 and overClinical endpointmedia_commonAged 80 and overHazard ratioHematologyMiddle AgedPrognosisTemsirolimusSurvival RateLocalOncology030220 oncology & carcinogenesisInjections IntravenousRefractory Mantle Cell LymphomaFemaleIntravenousmedicine.drugsafetymedicine.medical_specialtyoverall survivalmantle cell lymphomaAntineoplastic AgentsDrug Administration ScheduleInjections03 medical and health sciencesRefractoryInternal medicinemedicineHumansmedia_common.cataloged_instanceProgression-free survivalEuropean unionAgedSirolimusSalvage Therapybusiness.industryMantle-Cellmedicine.diseaseSurgeryNeoplasm RecurrenceDrug Resistance NeoplasmNeoplasmMantle cell lymphomaNeoplasm Recurrence Localbusinessprogression-free survivalFollow-Up Studies030215 immunology
researchProduct

Decayed, missing and filled teeth and dental anomalies in long term survived leukemic children: a prospective controlled study

2011

Objective: The aim of this prospective controlled study is the comparison between long-term children survived leukaemia and a control group in terms of the decayed, missing or filled permanent teeth (DMFT) and dental anomalies. Study design: Fifty-two long term children survived leukaemia, aged from 8 to 15 years (27 females, 25 males; mean age 11.5 years) were evaluated for the possible effects of the anti-leukaemic therapy on dental development and compared to a control group of 52 healthy children (27 females, 25 males, mean age 11 years). All long-term children who survived were at least 24 months in continuous complete remission. The study of the dental status with a routine oral exami…

MaleTime FactorsAdolescentDentistryOdontologíaOral hygienestomatognathic systemMicrodontiamedicineHumansProspective StudiesSurvivorsProspective cohort studyChildGeneral DentistryPermanent teethPaediatric patientsDental anomaliesbusiness.industryDMF IndexTooth Abnormalitiespediatric dentistry child leukemia leukemia survivorsMED/28 - MALATTIE ODONTOSTOMATOLOGICHEPrecursor Cell Lymphoblastic Leukemia-Lymphoma:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseCiencias de la saludDental carestomatognathic diseasesLeukemia Myeloid AcuteOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASSurgeryWho criteriaFemaleResearch-ArticleOdontostomatology for the Disabled or Special Patientsbusiness
researchProduct